Services

• We respond to clinical queries regarding adverse effects of therapeutic interventions and benefit/risk analysis in various patient subpopulations
• We create rapid reports of evidence for clinical decisions
• We provide second opinion services regarding therapeutic step-up strategies and/or discontinuation strategies
• We perform medical and scientific review of case reports of serious/non-serious adverse events from clinical trials or from post-marketing surveillance systems
• We offer research collaboration opportunities
• We design, develop and deliver training courses customized to specific needs, and provide interdisciplinary training of personnel on aspects of patient safety
• We provide mentoring activities for medical students and scientific professionals

• We respond to clinical queries regarding adverse effects of therapeutic interventions and benefit/risk analysis in various patient subpopulations
• We provide information on applicable Clinical Pathway Programs & Partnership Programs (e.g. The Human Genome Project, EMBL-EBI)
• We create rapid reports of evidence for clinical decisions
• We provide consulting services on aspects that compound uncertainty in precision medicine (incl. off-label use in oncology)
• We provide second opinion services regarding therapeutic step-up strategies, therapy optimization and/or discontinuation strategies
• We perform medical and scientific review of case reports of serious/non-serious adverse events from clinical trials and/or from post-marketing surveillance systems
• We offer research collaboration opportunities
• We design, develop and deliver training courses customized to specific needs, and provide interdisciplinary training of personnel on aspects of patient safety
• We provide mentoring activities for medical students and medical-scientific professionals regarding patient safety and reporting obligations of adverse events

• We provide consulting services for the management of burn-out syndrome (all stages)
• We respond to clinical queries regarding adverse effects of therapeutic interventions and benefit/risk analysis in various patient subpopulations
• We create rapid reports of evidence for clinical decisions
• We provide consulting services on aspects that compound uncertainty (incl. therapy-resistant depression)
• We perform medical and scientific review of case reports of serious/non-serious adverse events from clinical trials and/or from post-marketing surveillance systems

• We provide consulting and laboratory services (part of a pilot project) for the diagnostic of rare diseases e.g. Lysosomal Acid Lipase Deficiency (LAL-D)
• We provide consulting services for the indication of contrast-enhanced ultrasound (CEUS) examinations of the liver
• We respond to clinical queries regarding adverse effects of therapeutic interventions and benefit/risk analysis in various patient subpopulations
• We create rapid reports of evidence for clinical decisions
• We perform medical and scientific review of case reports of serious/non-serious adverse events from clinical trials and/or from post-marketing surveillance systems

Since 1993, the AMSP project (i.e. Germ. Arzneimittelsicherheit in der Psychiatrie) systematically documents and analyzes adverse drug reactions of psychotropic drugs with the aim of increasing the safety of treatment through documentation and further education.

• We respond to clinical queries from AMSP members (psychiatry clinics/hospitals in Germany, Austria, Switzerland) regarding adverse effects of therapeutic interventions and benefit/risk analysis in various patient subpopulations (including in the elderly)
• We create rapid reports of evidence for clinical decisions (including review of selected, published medical-scientific literature)
• We provide consulting services on aspects that compound uncertainty (incl. off-label use of psychotropic drugs for dementia)
• We perform medical and scientific review of case reports of serious/non-serious adverse events from clinical trials and/or from post-marketing surveillance systems
• We perform signal detection for pharmacovigilance activities

Founded by Rudolf Juchems, M.D., the Mayo Alumni German Speaking Chapter (MAGSC) hosted its first scientific meeting in Bonn in 1996 (reported on in Mayo Alumni magazine, Fall 2005, Volume 41, No 4, 14-15). Dr. Juchems was a cardiologist specializing in internal Intensive Care Medicine and a member and board member of numerous scientific societies in Germany and abroad. He was a member of the Doctors Mayo Society and the Plummer Society as well as a honorary member of the European Council of Emergency Medical Care and Resuscitation Medicine. Dr. Juchems passed away in 2008 and the annual MAGSC scientific award is named in his honor.

• We participate in annual scientific meetings and provide collaboration opportunities

As a member of the Special Interest Group Clinical Pharmacometrics we are involved in the Education Task Force and support medical universities with sources and guidance for curriculum development, mentoring activities, and drug safety research (incl. disease progression modeling projects).